NTT Biopharma PIPELINE

Platform Technologies

Brain Delivery Ocular Delivery (Eyedrop Nanoformulation) Nucleic Acid Delivery Oral Peptide Delivery Active Targeting Nanoparticle

Brain Disease

NTT-001 DNA Plasmid (IV Injection for PD)

Cancer Therapy

NTT-002

Ocular Disease

NTT-003 (Eyedrop Formulation for Wet-AMD) ASO (Eyedrop Formulation for Wet-AMD) Therapeutic Peptide (Eyedrop Formulation for Dry-AMD)

Oral Delivery Platform

Summary

• API Protection: MSN can shield peptides from gastrointestinal degradation.

• Enhanced Bioavailability: The small particle size and tunable surface properties of MSNs facilitate peptide transport across the intestinal barrier, improving oral bioavailability.

• Broad Applications: MSNs offer a versatile oral delivery platform suitable for a wide range of peptide therapeutics.

Oral Formulation of GLP-1 Analogs

• MSN can efficiently load GLP-1 anaologs, including semaglutide, liraglutide, etc.

• MSN encapsulation extended the stability of GLP-1 peptides in protease from less than 20 minutes to more than 3 hours.

• Semaglutide in MSN oral nanoformulation demonstrated significant blood glucose reduction in diabetic animal models, offering a promising oral alternative to current therapies.